Literature DB >> 32930962

Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Gaurav Pandey1, Vibin Ramakrishnan2.   

Abstract

Advancements in medical science have facilitated in extending human lives. The increased life expectancy, though, has come at a cost. The cases of an aging population suffering from degenerative diseases like Alzheimer's disease (AD) are presently at its all-time high. Amyloidosis disorders such as AD are triggered by an abnormal transition of soluble proteins into their highly ordered aggregated forms. The landscape of amyloidosis treatment remains unchanged, and there is no cure for such disorders. However, an increased understanding of the mechanism of amyloid self-assembly has given hope for a possible therapeutic solution. In this review, we will discuss the current state of molecular and non-molecular options for therapeutic intervention of amyloidosis. We highlight the efficacy of non-invasive physical therapies as possible alternatives to their molecular counterparts. Graphical abstract.

Entities:  

Keywords:  Aggregation; Amyloid-beta; Non-invasive therapies; Protein folding; Protein misfolding diseases; Tau

Year:  2020        PMID: 32930962      PMCID: PMC7575678          DOI: 10.1007/s12551-020-00752-y

Source DB:  PubMed          Journal:  Biophys Rev        ISSN: 1867-2450


  125 in total

1.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

2.  Fibrillar disruption by AC electric field induced oscillation: A case study with human serum albumin.

Authors:  Shubhatam Sen; Monojit Chakraborty; Snigdha Goley; Swagata Dasgupta; Sunando DasGupta
Journal:  Biophys Chem       Date:  2017-04-13       Impact factor: 2.352

3.  Clinical trial of blood-brain barrier disruption by pulsed ultrasound.

Authors:  Alexandre Carpentier; Michael Canney; Alexandre Vignot; Vincent Reina; Kevin Beccaria; Catherine Horodyckid; Carine Karachi; Delphine Leclercq; Cyril Lafon; Jean-Yves Chapelon; Laurent Capelle; Philippe Cornu; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Sci Transl Med       Date:  2016-06-15       Impact factor: 17.956

Review 4.  Aβ42 and Aβ40: similarities and differences.

Authors:  Tian Qiu; Qian Liu; Yong-Xiang Chen; Yu-Fen Zhao; Yan-Mei Li
Journal:  J Pept Sci       Date:  2015-05-28       Impact factor: 1.905

5.  The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.

Authors:  Stina Tucker; Christer Möller; Karin Tegerstedt; Anna Lord; Hanna Laudon; Johan Sjödahl; Linda Söderberg; Erika Spens; Charlotte Sahlin; Erik Rollman Waara; Andrew Satlin; Pär Gellerfors; Gunilla Osswald; Lars Lannfelt
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Electric Field Effects on Short Fibrils of Aβ Amyloid Peptides.

Authors:  Francesca Lugli; Francesca Toschi; Fabio Biscarini; Francesco Zerbetto
Journal:  J Chem Theory Comput       Date:  2010-11-09       Impact factor: 6.006

Review 7.  Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies.

Authors:  Francisco J Carvajal; Hayley A Mattison; Waldo Cerpa
Journal:  Neural Plast       Date:  2016-08-18       Impact factor: 3.599

Review 8.  Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.

Authors:  Katie L Stewart; Sheena E Radford
Journal:  Biophys Rev       Date:  2017-06-19

9.  Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Authors:  Gordon K Wilcock; Serge Gauthier; Giovanni B Frisoni; Jianping Jia; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Bjoern O Schelter; Damon J Wischik; Charles S Davis; Roger T Staff; Vesna Vuksanovic; Trevor Ahearn; Luc Bracoud; Kohkan Shamsi; Ken Marek; John Seibyl; Gernot Riedel; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 10.  Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?

Authors:  Vanessa de Jesus R de Paula; Fabiana Meira Guimarães; Breno Satler Diniz; Orestes Vicente Forlenza
Journal:  Dement Neuropsychol       Date:  2009 Jul-Sep
View more
  3 in total

Review 1.  CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics.

Authors:  Shanu Bhardwaj; Kavindra Kumar Kesari; Mahesh Rachamalla; Shalini Mani; Ghulam Md Ashraf; Saurabh Kumar Jha; Pravir Kumar; Rashmi K Ambasta; Harish Dureja; Hari Prasad Devkota; Gaurav Gupta; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Janne Ruokolainen; Mohammad Amjad Kamal; Shreesh Ojha; Niraj Kumar Jha
Journal:  J Adv Res       Date:  2021-07-06       Impact factor: 12.822

Review 2.  Therapeutic non-invasive brain treatments in Alzheimer's disease: recent advances and challenges.

Authors:  Chongyun Wu; Luoman Yang; Shu Feng; Ling Zhu; Luodan Yang; Timon Cheng-Yi Liu; Rui Duan
Journal:  Inflamm Regen       Date:  2022-10-03

3.  Biophysical Reviews: a Q1 ranked journal in biophysics and structural biology.

Authors:  Damien Hall
Journal:  Biophys Rev       Date:  2020-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.